Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20307053 | 0.86 | AGXT (0.52) | BACE1AGXTACACBACACAHTR7 | |
| SCHEMBL7139498 | 0.83 | AGXT (0.53) | MAOBTAAR1BACE1AGXTCYP3A4 | |
| SCHEMBL7146312 | 0.82 | GFER (0.52) | MAOBTAAR1CYP19A1NPC1RAB9A | |
| SCHEMBL29684100 | 0.80 | MAOB (0.59) | MAOBTAAR1CYP19A1NPC1RAB9A | |
| SCHEMBL6678878 | 0.80 | MAOB (0.59) | MAOBTAAR1CYP19A1NPC1RAB9A | |
| SCHEMBL7901300 | 0.78 | ENPP2 (0.46) | TAAR1ACACBACACA | |
| SCHEMBL1337731 | 0.77 | BCL2 (0.59) | MAOBTAAR1CYP19A1BACE1AGXT | |
| SCHEMBL1048793 | 0.77 | TAAR1 (0.61) | MAOBTAAR1CYP3A4HTR7 | |
| SCHEMBL5659 | 0.76 | GFER (0.59) | MAOBTAAR1CYP19A1NPC1RAB9A | |
| SCHEMBL3720966 | 0.74 | LOXL2 (0.56) | MAOBTAAR1AGXTCYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0789577-B1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-0671928-B1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1258492-A1 | N-substituted oligomers and methods for their synthesis, e.g. polyglycine bearing nucleic acid bases | CHIRON CORPORATION (US) | 2002-11-20 | — | — | EP | disclosed |
| US-5977301-A | AUTOMATED AND EFFICIENT SYNTHESIS BY REACTING SOLID SUPPORT BOUND AMINE WITH AN ACYLATING SUBMONOMER TO PRODUCE A SOLID SUPPORT-BOUND AMIDE WHICH CAN BE FURTHER REACTED; ONLY REACTIVE SIDE CHAINS NEED PROTECTED | CHIRON CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5877278-A | SOLID PHASE SYNTHESIS USING TWO SUBMONOMERS-AN ACYLATING AGENT, E.G. A HALOACETIC ACID, AND A PRIMARY AMINE; CYCLIZATION TO PRODUCE MIMETICS OF DRUGS; ELIMINATION OF THE NECESSITY OF PROTECTION GROUPS | CHIRON CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5831005-A | ACYLATION, NUCLEOPHILIC DISPLACEMENT CYCLES | CHIRON CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0671928-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS. | CHIRON CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| US-5480871-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0671928-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1995-09-20 | — | — | EP | disclosed |
| US-5447916-A | Hypotensive agents | CHIRON CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
| WO-1995004072-A1 | PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1994006451-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1994-03-31 | — | — | WO | disclosed |